TCGA-A2-A0CO-01A-13R-A22K-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 49
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.600
- IL6_JAK_STAT3_SIGNALING+0.520
- INTERFERON_GAMMA_RESPONSE+0.520
- INFLAMMATORY_RESPONSE+0.510
- INTERFERON_ALPHA_RESPONSE+0.510
- ALLOGRAFT_REJECTION+0.440
- IL2_STAT5_SIGNALING+0.410
- MYOGENESIS+0.410
- ANGIOGENESIS+0.400
- KRAS_SIGNALING_UP+0.400
Top 10 suppressed
- E2F_TARGETS-0.720
- MYC_TARGETS_V1-0.680
- G2M_CHECKPOINT-0.650
- PROTEIN_SECRETION-0.590
- MTORC1_SIGNALING-0.510
- MYC_TARGETS_V2-0.470
- OXIDATIVE_PHOSPHORYLATION-0.470
- UNFOLDED_PROTEIN_RESPONSE-0.430
- DNA_REPAIR-0.420
- GLYCOLYSIS-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-XX-A899-01A-11R-A36F-07 | — | A | 0.962 |
| 2 | sclcA055A_S52.txt | — | cohortMD2 | 0.957 |
| 3 | TCGA-GM-A4E0-01A-12R-A266-07 | — | A | 0.949 |
| 4 | TCGA-60-2715-01A-01R-0851-07 | — | cohortSQ1 | 0.949 |
| 5 | SRR2771286 | — | — | 0.948 |
| 6 | BS_Z28VKGNS | Neurofibroma | — | 0.945 |
| 7 | a802b49c.736d.427c.bcca.8375c4171284 | — | cohortA1 | 0.943 |
| 8 | BS_NQB91P48 | pilocytic astrocytoma | — | 0.938 |
| 9 | TCGA-99-AA5R-01A-11R-A39D-07 | — | cohortA1 | 0.938 |
| 10 | TCGA-56-8623-01A-11R-A28V-07 | — | cohortA1 | 0.937 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.600 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.520 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.520 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.510 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.510 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.440 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.410 | Idelalisib | — uncovered |
| MYOGENESIS | 0.410 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.400 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.380 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.380 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.340 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.330 | Inavolisib | — uncovered |
| COAGULATION | 0.330 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.330 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.330 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.290 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.280 | Idelalisib | — uncovered |
| HYPOXIA | 0.240 | Idelalisib | — uncovered |